Literature DB >> 34514087

Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Chiara Rinoldi1, Seyed Shahrooz Zargarian1, Pawel Nakielski1, Xiaoran Li2, Anna Liguori3, Francesca Petronella4, Dario Presutti5, Qiusheng Wang2, Marco Costantini5, Luciano De Sio6,7, Chiara Gualandi3,8, Bin Ding2, Filippo Pierini1.   

Abstract

In recent years, the main quest of science has been the pioneering of the groundbreaking biomedical strategies needed for achieving a personalized medicine. Ribonucleic acids (RNAs) are outstanding bioactive macromolecules identified as pivotal actors in regulating a wide range of biochemical pathways. The ability to intimately control the cell fate and tissue activities makes RNA-based drugs the most fascinating family of bioactive agents. However, achieving a widespread application of RNA therapeutics in humans is still a challenging feat, due to both the instability of naked RNA and the presence of biological barriers aimed at hindering the entrance of RNA into cells. Recently, material scientists' enormous efforts have led to the development of various classes of nanostructured carriers customized to overcome these limitations. This work systematically reviews the current advances in developing the next generation of drugs based on nanotechnology-assisted RNA delivery. The features of the most used RNA molecules are presented, together with the development strategies and properties of nanostructured vehicles. Also provided is an in-depth overview of various therapeutic applications of the presented systems, including coronavirus disease vaccines and the newest trends in the field. Lastly, emerging challenges and future perspectives for nanotechnology-mediated RNA therapies are discussed.
© 2021 Wiley‐VCH GmbH.

Entities:  

Keywords:  COVID‐19; drug delivery; nanostructured biomaterials; personalized therapy; ribonucleic acids

Mesh:

Substances:

Year:  2021        PMID: 34514087      PMCID: PMC8420172          DOI: 10.1002/smtd.202100402

Source DB:  PubMed          Journal:  Small Methods        ISSN: 2366-9608


  361 in total

1.  Dual-promoter lentiviral vectors for constitutive and regulated gene expression in neurons.

Authors:  Sergio Gascón; Juan A Paez-Gomez; Margarita Díaz-Guerra; Peter Scheiffele; Francisco G Scholl
Journal:  J Neurosci Methods       Date:  2007-09-29       Impact factor: 2.390

2.  Green nanoparticles for oligonucleotide delivery.

Authors:  Yuanyu Zhang; Jun Ge
Journal:  Gene Ther       Date:  2020-07-10       Impact factor: 5.250

3.  Near-infrared remotely triggered drug-release strategies for cancer treatment.

Authors:  Amanda M Goodman; Oara Neumann; Kamilla Nørregaard; Luke Henderson; Mi-Ran Choi; Susan E Clare; Naomi J Halas
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

Review 4.  Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes.

Authors:  Nuphar Veiga; Yael Diesendruck; Dan Peer
Journal:  Adv Drug Deliv Rev       Date:  2020-04-13       Impact factor: 15.470

5.  An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

Authors:  Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

6.  Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

Authors:  Xuling Zhu; Ling Yin; Matt Theisen; Jenny Zhuo; Summar Siddiqui; Becca Levy; Vladimir Presnyak; Andrea Frassetto; Jaclyn Milton; Timothy Salerno; Kerry E Benenato; Joe Milano; Andy Lynn; Staci Sabnis; Kristine Burke; Gilles Besin; Christine M Lukacs; Lin T Guey; Patrick F Finn; Paolo G V Martini
Journal:  Am J Hum Genet       Date:  2019-03-14       Impact factor: 11.025

7.  Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.

Authors:  Xiao-Lei Shi; Yuan Li; Lu-Ming Zhao; Lin-Wang Su; Gang Ding
Journal:  Colloids Surf B Biointerfaces       Date:  2018-09-29       Impact factor: 5.268

8.  Photoresponsive miR-34a/Nanoshell Conjugates Enable Light-Triggered Gene Regulation to Impair the Function of Triple-Negative Breast Cancer Cells.

Authors:  Megan N Dang; Carolina Gomez Casas; Emily S Day
Journal:  Nano Lett       Date:  2020-12-11       Impact factor: 11.189

9.  Engineered Human Adipose Stem-Cell-Derived Exosomes Loaded with miR-21-5p to Promote Diabetic Cutaneous Wound Healing.

Authors:  Qijun Lv; Junfeng Deng; You Chen; Yizhen Wang; Bo Liu; Jie Liu
Journal:  Mol Pharm       Date:  2020-04-13       Impact factor: 4.939

View more
  6 in total

Review 1.  Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis.

Authors:  Xiaoxin Li; Hongzhao Qi; Weigang Cui; Zhibin Wang; Xiuxiu Fu; Tianxiang Li; Huibo Ma; Yanyan Yang; Tao Yu
Journal:  Mol Ther       Date:  2022-08-01       Impact factor: 12.910

Review 2.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 3.  Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review.

Authors:  Adekunle Sanyaolu; Chuku Okorie; Aleksandra Marinkovic; Stephanie Prakash; Martina Williams; Nafees Haider; Jasmine Mangat; Zaheeda Hosein; Vyshnavy Balendra; Abu Fahad Abbasi; Priyank Desai; Isha Jain; Stephen Utulor; Amos Abioye
Journal:  Ther Adv Vaccines Immunother       Date:  2022-05-30

4.  Macrophage-targeting gene silencing orchestrates myocardial microenvironment remodeling toward the anti-inflammatory treatment of ischemia-reperfusion (IR) injury.

Authors:  Yao Wang; Mengying Hou; Shanzhou Duan; Ziyin Zhao; Xuejie Wu; Yongbing Chen; Lichen Yin
Journal:  Bioact Mater       Date:  2022-02-01

5.  Cardiomyocyte-targeted anti-inflammatory nanotherapeutics against myocardial ischemia reperfusion (IR) injury.

Authors:  Min Lan; Mengying Hou; Jing Yan; Qiurong Deng; Ziyin Zhao; Shixian Lv; Juanjuan Dang; Mengyuan Yin; Yong Ji; Lichen Yin
Journal:  Nano Res       Date:  2022-07-27       Impact factor: 10.269

6.  NIR-Absorbing Mesoporous Silica-Coated Copper Sulphide Nanostructures for Light-to-Thermal Energy Conversion.

Authors:  Elisabetta Fanizza; Rita Mastrogiacomo; Orietta Pugliese; Alexa Guglielmelli; Luciano De Sio; Rachele Castaldo; Maria Principia Scavo; Mariangela Giancaspro; Federica Rizzi; Gennaro Gentile; Fabio Vischio; Livianna Carrieri; Ilaria De Pasquale; Giacomo Mandriota; Francesca Petronella; Chiara Ingrosso; Marino Lavorgna; Roberto Comparelli; Marinella Striccoli; Maria Lucia Curri; Nicoletta Depalo
Journal:  Nanomaterials (Basel)       Date:  2022-07-24       Impact factor: 5.719

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.